Indian pharmaceutical company Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) (BSE:524715) confirmed on Monday that it has completed its merger with Taro Pharmaceutical Industries Ltd (NYSE:TARO), an Israeli research-based pharmaceutical company.
Sun acquired all outstanding Taro shares, making Taro a wholly-owned subsidiary. This strengthens Sun Pharma's position in the competitive generics market by combining their strengths and capabilities.
Sun has been Taro's majority shareholder since 2010.
Hikma Pharmaceuticals extends KLOXXADO nasal spray shelf-life 8mg from 24 to 36 months
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)